Balyasny Asset Management
NAGE

Balyasny Asset Management’s Niagen Bioscience NAGE Stock Holding History

Balyasny Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,990
Closed -$62.6K – 3217
2024
Q1 		$62.6K Buy
+17,990
New +$33.3K ﹤0.01% 2518
2022
Q3 		– Sell
-12,105
Closed -$20K – 3333
2022
Q2 		$20K Buy
+12,105
New +$23.7K ﹤0.01% 2483

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Balyasny Asset Management's NAGE Position: Q2 2024 in Review

Balyasny Asset Management sold out of Niagen Bioscience (NAGE) in Q2 2024, closing a stake of 17,990 shares — an estimated $62.6K sold.

Balyasny Asset Management first reported a position in NAGE in Q2 2022 and held it in 2 quarters. The position peaked at $62.6K in Q1 2024. 78 funds tracked by Wall St. Rank hold NAGE as of Q2 2024.

  • Balyasny Asset Management reported no remaining Niagen Bioscience position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 17,990 Niagen Bioscience shares in Q2 2024, an estimated $62.6K.
  • Balyasny Asset Management first reported a position in Niagen Bioscience in Q2 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Niagen Bioscience position peaked at $62.6K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.